AU7000094A - Indolocarbazole compound useful as proteinkinase c inhibitor - Google Patents

Indolocarbazole compound useful as proteinkinase c inhibitor

Info

Publication number
AU7000094A
AU7000094A AU70000/94A AU7000094A AU7000094A AU 7000094 A AU7000094 A AU 7000094A AU 70000/94 A AU70000/94 A AU 70000/94A AU 7000094 A AU7000094 A AU 7000094A AU 7000094 A AU7000094 A AU 7000094A
Authority
AU
Australia
Prior art keywords
proteinkinase
inhibitor
compound useful
indolocarbazole compound
indolocarbazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU70000/94A
Other languages
English (en)
Inventor
Oreste Ghisalba
Pascale Hoehn-Thierry
Theophile Moerker
Heinrich Peter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of AU7000094A publication Critical patent/AU7000094A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/465—Streptomyces

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU70000/94A 1993-06-17 1994-06-09 Indolocarbazole compound useful as proteinkinase c inhibitor Abandoned AU7000094A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP93810437 1993-06-17
EP93810437 1993-06-17
PCT/EP1994/001883 WO1995000520A1 (en) 1993-06-17 1994-06-09 Indolocarbazole compound useful as proteinkinase c inhibitor

Publications (1)

Publication Number Publication Date
AU7000094A true AU7000094A (en) 1995-01-17

Family

ID=8214987

Family Applications (1)

Application Number Title Priority Date Filing Date
AU70000/94A Abandoned AU7000094A (en) 1993-06-17 1994-06-09 Indolocarbazole compound useful as proteinkinase c inhibitor

Country Status (4)

Country Link
EP (1) EP0703917A1 (de)
JP (1) JPH08511785A (de)
AU (1) AU7000094A (de)
WO (1) WO1995000520A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5827846A (en) * 1994-06-01 1998-10-27 Novartis Corp. Carbazole derivatives as agents against multi-drug resistance
EP0763042A1 (de) * 1994-06-01 1997-03-19 Novartis AG Polycyclische lactamderivate zur sensibilisierung resistenter zellen gegen antitumormittel
EP0763041A1 (de) * 1994-06-01 1997-03-19 Novartis AG Indolocarbazol-derivate zur sensibilisierung resistenter zellen gegen antitumormittel
AU715527B2 (en) * 1995-06-27 2000-02-03 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
US6274576B1 (en) 1995-06-27 2001-08-14 The Henry Jackson Foundation For The Advancement Of Military Medicine Method of dynamic retardation of cell cycle kinetics to potentiate cell damage
US6210935B1 (en) 1995-08-30 2001-04-03 Novartis Ag Staurosporin biosynthesis gene clusters
UA67725C2 (en) 1996-06-03 2004-07-15 Cephalon Inc K-252a derivatives and a method for improvement of functioning and cell survival enhancement
US6875865B1 (en) 1996-06-03 2005-04-05 Cephalon, Inc. Selected derivatives of K-252a
RU2183959C2 (ru) 1996-06-25 2002-06-27 Сефалон, Инк. Применение производных к-252а для лечения расстройств периферической или центральной нервной системы и избыточной выработки цитокина
IL128494A0 (en) * 1996-08-30 2000-01-31 Lilly Co Eli Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
WO1998008510A1 (en) * 1996-08-30 1998-03-05 Eli Lilly And Company Use of inhibitors of pkc for the manufacture of a medicament for the treatment of central nervous system diseases associated with hiv infection
CO4940430A1 (es) * 1997-07-07 2000-07-24 Novartis Ag Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales
US6242473B1 (en) * 1999-01-08 2001-06-05 Maxim Pharmaceuticals, Inc. Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
CN104593281A (zh) * 2013-10-31 2015-05-06 王林 几个具有强杀虫活性的吲哚咔唑生物碱及产生菌株
CN107603922B (zh) * 2017-11-06 2019-10-18 海南大学 海绵共生链霉菌及其发酵生产星形孢菌素的方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0383919A4 (en) * 1988-02-04 1992-08-05 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
AU7035991A (en) * 1989-12-14 1991-07-18 Schering Corporation Indolocarbazoles from saccharothrix aerocolonigenes subsp. copiosa subsp. nov. scc 1951 atcc 53856

Also Published As

Publication number Publication date
WO1995000520A1 (en) 1995-01-05
EP0703917A1 (de) 1996-04-03
JPH08511785A (ja) 1996-12-10

Similar Documents

Publication Publication Date Title
AU1272295A (en) Proinsulin-like compounds
AU6971794A (en) Novel compounds
AU3629693A (en) Heterobicyclic compounds
AU7000094A (en) Indolocarbazole compound useful as proteinkinase c inhibitor
AU2131192A (en) Maillard reaction inhibitor
AU3803593A (en) Compounds
GB9315914D0 (en) Novel compound
AU5161593A (en) Heterocyclic compound
AU4982293A (en) Novel heterocyclic compound
AU5261093A (en) Aminoalkylphenyl compounds
AU613302B2 (en) Quinolyloxazole-2-ones useful as proteinkinase c inhibitors
GB9302569D0 (en) Novel compound
AU679513B2 (en) Novel photochromic compound
AU6571594A (en) Thioindole pyperidinyl derivatives used as antalgics
AU7843394A (en) Antiviral compounds
AU2836895A (en) Fulgimide compound
AU1115195A (en) Disazo compound
AU6593090A (en) Novel pyridyloxyazole-2-ones useful as proteinkinase c inhibitors
GB9302567D0 (en) Novel compound
AU2159392A (en) Renin inhibiting compounds
AU5285593A (en) Azole compound
AU6413594A (en) Substituted 3-phenanthridinone derivatives as 5alpha-reductase inhibitors
AU5394594A (en) New compounds
AU7693394A (en) Brightening mixtures based on bistyryl compounds
AU6169294A (en) 15-oxasterols as hypocholesterolemics